A quick, and robust, and unbiased platform for circular RNAs isolation, discovery and profiling.
Award amount
$352,929Program and phase
SBIR · Phase IAward year
2023Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- RIBO-THERAPEUTICS LLC
- Proposal award date
- 2023-08-09
- Contract end date
- 2024-05-31
- UEI
- MKTKL4U2P7D1
- Solicitation number
- PA22-176
- Topic code
- NHGRI
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Platform to support clinical variant interpretation through probabilistic assessment of functional evidence
- Innovations to expand and accelerate the commercial impact of DNA modifications
- High-throughput Direct Sequencing and Quantitative Mapping of RNA Modifications using Mass Spectrometry.
- Super-resolution single-molecule sequencing by observing the dynamic hybridization of a repertoire of oligonucleotides to DNA targets
- Exhaustive de novo sequencing of every RNA in a sample by a layer-by-layer mass spectrometry ladder intensity approach.
Research funding history
2 SBIR/STTR records share this UEI (2021–2023). Reported award amounts total $654,747. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services